JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/ja
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

JP2000538720A 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用 Pending JP2002508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (ja) 2002-03-19
JP2002508338A5 true JP2002508338A5 (https=) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (ja) 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用

Country Status (6)

Country Link
EP (1) EP1037669A4 (https=)
JP (1) JP2002508338A (https=)
KR (1) KR20010033062A (https=)
AU (1) AU749059B2 (https=)
CA (1) CA2314683A1 (https=)
WO (1) WO1999030742A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
EP2215231A4 (en) 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3325579B2 (ja) * 1995-03-16 2002-09-17 久光製薬株式会社 新規遺伝子組換え体
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0863988A1 (en) * 1995-11-28 1998-09-16 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
AU1124997A (en) * 1995-11-28 1998-06-19 Johns Hopkins University School Of Medicine, The Conditionally replicating viral vectors and their use
WO1997031119A1 (en) * 1996-02-21 1997-08-28 Res Inst For Genetic And Human Methods and compositions for protective and therapeutic genetic immunization
JP2000506727A (ja) * 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
DE69737597D1 (de) * 1996-07-22 2007-05-24 Us Gov Health & Human Serv Vektoren zur inhibierung von viralem und tumorwachstum
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター

Similar Documents

Publication Publication Date Title
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
AU2002317841A1 (en) Use of fkbp chaperones as expression tool
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ES2113854T3 (es) Derivados de albumina con funciones terapeuticas.
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
JP2002508338A5 (https=)
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
WO1999065870A3 (en) Sulfonamide inhibitors of aspartyl protease
MY137777A (en) Inhibitors of aspartyl protease
DE60024419D1 (en) Aspartyl-protease-inhibitoren
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
NO940810L (no) Behandling av virusinfeksjoner
CA2195125A1 (en) Difluorostatone antiviral agents
BG101175A (bg) Тройна анти-нiv комбинация
JP2002523426A5 (https=)
EP0323157A3 (en) Antiviral compounds and methods
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
FI881123L (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
RU2003125554A (ru) Природные антитела, активные против вируса иммунодефицита человека (вич)
FR2647809B1 (fr) Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
FR2652091B1 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in-vitro des infections dues a ces virus.
WO1999061011A3 (de) Verwendung eines arzneimittels mit einem gehalt an tyrothricin zur behandlung von virusinfektionen